Compare Eli Lilly And Co (LLY) vs Tyson Foods, Inc. (TSN) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Tyson Foods (TSN) trades at $58.245, up 0.82% today, with a bearish technical signal but mixed earnings history. The company reported Q1 2026 EPS of $0.87, beating estimates, but faces margin pressures with a net income margin of 0.81%. Recent news highlights strategic product launches and executive appointments, while cash flow trends show operational strength but negative net cash flow in 2025.

Outlook is cautiously optimistic with a consensus price target of $68.80, implying 18% upside, supported by 50% analyst buy ratings. Risks include volatile protein markets and debt levels, but long-term growth in prepared foods and dividend stability offer value. Investors should weigh near-term margin challenges against strategic initiatives and analyst confidence.